LONDON – The Oxford University team behind the development of Astrazeneca plc’s COVID-19 vaccine have become the first to publish full and complete interim phase III data in a peer-reviewed journal.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aldeyra, Altimmune, Arena, Astrazeneca, Axsome, Bellus, Cardior, Curis, Domain, Harpoon, Larimar, Monopar, Novaliq, Panbela, Sojournix, Vicore, Xenon.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Alx, Arch Oncology, Arcturus, Arcutis, Brickell, Cel-Sci, Cytokinetics, Dare, Eisai, Genetx, Hookipa, Inovio, KPB, Lyra, Magenta, Neurorx, Odonate, Relief, Relmada, Sarepta, Tonix, Ultragenyx, Ysopia.

The independent data monitoring committee overseeing Cortexyme Inc.’s phase II/III trial of atuzaginstat (COR-388), a gingipain inhibitor for patients with Alzheimer’s disease, has recommended the study continue to its one-year endpoint.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Apeiron, Ascletis, Clover, Cortexyme, Precision, Takeda, Sutro.

The phase III study of Zepzelca (lurbinectedin) as combination therapy from Jazz Pharmaceuticals plc and Pharmamar SA was a stumble, but the companies said they found plenty of encouraging data prompting them to continue development.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alnylam, Axial, Enlivex, Evelo, F-star, Gemoab, IMV, Jazz, Pfizer, Pharmamar, Puretech, Qpex, Remynd, Resolve, Senhwa, Sirnaomics, Valneva.

Despite challenges tossed at the phase III study of mitapivat from Agios Pharmaceuticals Inc. by COVID-19, top-line data showed the oral therapy hit its primary endpoint in treating adults with pyruvate kinase (PK) deficiency who don’t receive regular transfusions.